Cognition Therapeutics, Inc. announced that the company has been awarded a Therapeutic Pipeline Program Grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). This grant will fund preclinical studies of two sigma-2 (s-2) receptor modulators in animal models of Parkinson's disease that will be led by Cognition Therapeutics' VP of research, Mary E. Hamby, Ph.D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.98 USD | +3.12% |
|
-3.88% | +7.03% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.03% | 7.69Cr | |
+20.17% | 13TCr | |
+24.67% | 12TCr | |
+25.44% | 2.77TCr | |
-17.74% | 2.03TCr | |
-15.17% | 1.68TCr | |
-15.21% | 1.56TCr | |
+11.91% | 1.48TCr | |
-47.10% | 1.46TCr | |
+54.50% | 1.44TCr |
- Stock Market
- Equities
- CGTX Stock
- News Cognition Therapeutics, Inc.
- Cognition Therapeutics, Inc. Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson's Disease